ELDN Eledon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELDN

Price (delayed)

$3.605

Market cap

$278.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

$272.67M

?
Relative Growth: Rel. Growth: 1
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring ...

Highlights
The debt has declined by 37% year-on-year and by 13% since the previous quarter
The quick ratio has declined by 39% year-on-year but it has increased by 13% since the previous quarter
The net income has plunged by 105% YoY and by 74% from the previous quarter
Eledon Pharmaceuticals's EPS has decreased by 48% QoQ and by 4.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://eledon.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ELDN

ELDN stock price

How has the Eledon Pharmaceuticals stock price performed over time
Intraday
3.3%
1 week
-6.85%
1 month
-4.63%
1 year
18.98%
YTD
138.74%
QTD
17.05%

Financial performance

How have Eledon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$86.47M
Net income
-$79.5M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 105% YoY and by 74% from the previous quarter
The operating income has declined by 11% year-on-year and by 3.9% since the previous quarter

Price vs fundamentals

How does ELDN's price correlate with its fundamentals

Growth

What is Eledon Pharmaceuticals's growth rate over time

Valuation

What is Eledon Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eledon Pharmaceuticals's EPS has decreased by 48% QoQ and by 4.1% YoY
The stock's price to book (P/B) is 69% more than its last 4 quarters average of 3.5
The company's equity fell by 45% QoQ and by 24% YoY

Efficiency

How efficient is Eledon Pharmaceuticals business performance
ELDN's return on assets has dropped by 100% year-on-year and by 78% since the previous quarter
The return on invested capital has dropped by 99% year-on-year and by 80% since the previous quarter
Eledon Pharmaceuticals's return on equity has shrunk by 86% QoQ and by 83% YoY

Dividends

What is ELDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELDN.

Financial health

How did Eledon Pharmaceuticals financials performed over time
Eledon Pharmaceuticals's total liabilities has increased by 43% from the previous quarter
The current ratio has declined by 39% year-on-year but it has increased by 14% since the previous quarter
The debt is 99% smaller than the equity
The company's equity fell by 45% QoQ and by 24% YoY
The debt has declined by 37% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.